Dosage forms of tissue kallikrein 1
US12329805B2 · kind B2 · utility
0Cited by
98References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 3, 2023 |
| Grant date | Jun 17, 2025 |
| Priority date | — |
| Expiry date | Nov 3, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/21035
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are dosage forms of one or more tissue kallikrein-1 (KLK1) polypeptides which have a total KLK1 polypeptide dosage of about 0.1 μg/kg to about 10.0 μg/kg, including subcutaneous and intravenous dosage forms. Also provided are related devices and methods of use thereof, for example, for treating ischemic and hemorrhagic conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.